KRYS
Price
$181.00
Change
+$6.42 (+3.68%)
Updated
Apr 2 closing price
Capitalization
5.21B
39 days until earnings call
VCEL
Price
$44.31
Change
+$1.23 (+2.86%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
2.22B
35 days until earnings call
Ad is loading...

KRYS vs VCEL

Header iconKRYS vs VCEL Comparison
Open Charts KRYS vs VCELBanner chart's image
Krystal Biotech
Price$181.00
Change+$6.42 (+3.68%)
Volume$235.74K
Capitalization5.21B
Vericel
Price$44.31
Change+$1.23 (+2.86%)
Volume$4.79K
Capitalization2.22B
KRYS vs VCEL Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. VCEL commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and VCEL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (KRYS: $174.58 vs. VCEL: $43.08)
Brand notoriety: KRYS and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 115% vs. VCEL: 104%
Market capitalization -- KRYS: $5.21B vs. VCEL: $2.22B
KRYS [@Biotechnology] is valued at $5.21B. VCEL’s [@Biotechnology] market capitalization is $2.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than VCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 3 TA indicator(s) are bullish while VCEL’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 3 bullish, 5 bearish.
  • VCEL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, VCEL is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -9.21% price change this week, while VCEL (@Biotechnology) price change was -10.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

VCEL is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.21B) has a higher market cap than VCEL($2.22B). VCEL has higher P/E ratio than KRYS: VCEL (221.55) vs KRYS (58.19). KRYS YTD gains are higher at: 15.537 vs. VCEL (-21.535). KRYS has higher annual earnings (EBITDA): 110M vs. VCEL (16.6M). KRYS has more cash in the bank: 598M vs. VCEL (116M). KRYS has less debt than VCEL: KRYS (7.26M) vs VCEL (98.8M). KRYS has higher revenues than VCEL: KRYS (291M) vs VCEL (237M).
KRYSVCELKRYS / VCEL
Capitalization5.21B2.22B235%
EBITDA110M16.6M663%
Gain YTD15.537-21.535-72%
P/E Ratio58.19221.5526%
Revenue291M237M123%
Total Cash598M116M516%
Total Debt7.26M98.8M7%
FUNDAMENTALS RATINGS
KRYS vs VCEL: Fundamental Ratings
KRYS
VCEL
OUTLOOK RATING
1..100
7563
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
1852
SMR RATING
1..100
6885
PRICE GROWTH RATING
1..100
4763
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as VCEL (89) in the Medical Specialties industry. This means that KRYS’s stock grew similarly to VCEL’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for VCEL (52) in the Medical Specialties industry. This means that KRYS’s stock grew somewhat faster than VCEL’s over the last 12 months.

KRYS's SMR Rating (68) in the Pharmaceuticals Major industry is in the same range as VCEL (85) in the Medical Specialties industry. This means that KRYS’s stock grew similarly to VCEL’s over the last 12 months.

KRYS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as VCEL (63) in the Medical Specialties industry. This means that KRYS’s stock grew similarly to VCEL’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as VCEL (100) in the Medical Specialties industry. This means that KRYS’s stock grew similarly to VCEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSVCEL
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 15 days ago
76%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 6 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
69%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGLYX15.940.04
+0.25%
JPMorgan Small Cap Growth R4
PABGX163.46N/A
N/A
T. Rowe Price Blue Chip Growth Advisor
MDDIX9.84N/A
N/A
MassMutual Diversified Value I
EAGCX18.25N/A
N/A
Eaton Vance Atlanta Capital Focused Gr C
RSGFX10.45N/A
N/A
Victory RS Select Growth C

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+3.68%
IDYA - KRYS
51%
Loosely correlated
+10.70%
ACLX - KRYS
48%
Loosely correlated
+10.76%
CRNX - KRYS
48%
Loosely correlated
+2.51%
ZLDPF - KRYS
45%
Loosely correlated
+0.22%
PRME - KRYS
45%
Loosely correlated
+0.28%
More

VCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCEL
1D Price
Change %
VCEL100%
-3.44%
VCYT - VCEL
52%
Loosely correlated
-0.30%
BEAM - VCEL
41%
Loosely correlated
-9.70%
AXON - VCEL
38%
Loosely correlated
+2.90%
KRYS - VCEL
37%
Loosely correlated
-3.17%
RXRX - VCEL
37%
Loosely correlated
-3.69%
More